Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 194-200

  Hagen, Rachel M ^a   Chedea, Veronica S ^a,b   Mintoff, Christopher P ^a   Bowler, Elizabeth ^a   Morse, H Ruth ^a   Ladomery, Michael R ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b Laboratory of Animal Biology   (Romania)

Author keywords

Alternative splicing; Apoptosis; Caspase 9; Epigallocatechin 3 gallate; Flavonoids; Prostate cancer

Indexed keywords

CASPASE 9; CASPASE 9A; CISPLATIN; EPIGALLOCATECHIN GALLATE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 9; CATECHIN; CELL LINE, TUMOR; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 84879668883     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1920     Document Type: Article

References (38)

1. Bettuzzi S, Brausi M, Rizzi F, Peracchia G and Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Am Assoc Cancer Res 66: 1234-1240, 2006. (Pubitemid 43165995)
2. Hsieh TC and Wu JM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein, and quercetin. Anticancer Res 29: 4025-4032, 2009.
3. Stuart Ec, Scandlyn MJ and Rosengren RJ: Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. Life Sci 79: 2329-2336, 2006. (Pubitemid 44772933)
4. Chen D and Dou QP: Tea polyphenols and their roles in cancer prevention and chemotherapy. Int J Mol Sci 9: 1196-1206, 2008.
5. Philips BJ, Coyle CH, Morrisroe SN, Chancellor MB and Yoshimura N: Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res 30: 207-215, 2009.
6. Manoharan M, Fatima I, Saxena R, Chandra V, Sankhwar PL and Dwivedi A: (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem: Sep 5, 2012 (Epub ahead of print).
7. Lim YC and Cha YY: Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. J Surg Oncol 104: 776-780, 2011.
8. Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D and Watanabe N: (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by downregulating survivin expression. Int J Oncol 38: 1403-1408, 2011.
9. Shen Q, Tian F, Jiang P, Li Y, Zhang L, Lu J and Li J: EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci 29: 771-775, 2009.
10. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27: 2055-2063, 2007. (Pubitemid 351442738)
11. Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, Ho CT and Way TD: (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem 60: 2480-2489, 2012.
12. Singh M, Singh R, Bhui K, Tyagi S, Mahmood Z and Shukla Y: Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer cells. Oncol Res 19: 245-257, 2011.
13. Das A, Banik NL and Ray SK: Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer 116: 164-176, 2009.
14. Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, Yu A and Yang CS: Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 31: 902-910, 2010.
15. Min NY, Kim JH, Choi JH, Liang W, Ko YJ, Rhee S, Bang H, Ham SW, Park AJ and Lee KH: Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biomed Biophys Res Commun 421: 91-97, 2012.
16. Markus MA, Marques FZ and Morris BJ: Resveratrol, by modulating RNA processing factor levels, can influence the alternative splicing of pre-mRNAs. PLoS One 6: e28926, 2011.
17. Anderson SL, Qiu J and Rubin BY: EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 310: 627-633, 2003. (Pubitemid 37163710)
18. Kim MH: Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J Cell Biochem 104: 1491-1499, 2008.
19. David CJ and Manley JL: Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24: 2343-2364, 2010.
20. Miura K, Fujibuchi W and Unno M: Splice variants in apoptotic pathway. Exp Oncol 34: 212-217, 2012.
21. Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD and Chalfant CE: Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 70: 9185-9196, 2010.
22. Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A, Hawkins AJ, Mukerjee P, Pinkerman RL, Park MA and Chalfant CE: SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 9: 889-900, 2011.
23. Rasmussen R: Quantification on the LightCycler. In: Rapid Cycle Real-Time PCR, Methods and Applications. Meuer S, Wittwer C and Nakagawara K (eds). Springer Press, Heidelberg, 2001.
24. Applied Biosystems: Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR, 2008.
25. Havsteen BH: The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96: 67-202, 2002.
26. Crespy V, Morand C, Manach C, Besson C, Demigne C and Remesy C: Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol 277: G120-G126, 1999. (Pubitemid 29352652)
27. Pforte H, Hempel J and Jacobasch G: Distribution pattern of a flavonoid extract in the gastrointestinal lumen and wall of rats. Nahrung 43: 205-208, 1999. (Pubitemid 129570450)
28. Albrecht DS, Clubbs EA, Ferruzzi M and Bomser JA: Epigallocatechin-3- gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem Biol Interact 171: 89-95, 2008. (Pubitemid 350191843)
29. Yu HN, Shen SR and Yin JJ: Effects of interactions of EGCG and cd(2+) on the growth of PC-3 cells and their mechanisms. Food Chem Toxicol 45: 244-249, 2007.
30. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S and Corti A: The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 25: 2217-2224, 2004. (Pubitemid 39534860)
31. Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K and Kitajima M: Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 62: 135-138, 1996. (Pubitemid 26196511)
32. Chan MM, Soprano KJ, Weinstein K and Fong D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207: 389-396, 2006.
33. Yunos NM, Beale P, Yu JQ and Huq F: Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. Anticancer Res 31: 4283-4289, 2011.
34. Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H and Heber D: Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr 136: 1839-1843, 2006. (Pubitemid 43973585)
35. Rohde J, Jacobsen C and Kromann-Andersen H: Toxic hepatitis triggered by green tea. Ugeskr Laeger 173: 205-206, 2011.
36. Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y and Gupta KC: Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol 7: 202, 2011.
37. Ge J, Tan BX, Chen Y, Yang L, Peng XC, Li HZ, Lin HJ, Zhao Y, Wei M, Cheng K, Li LH, Dong H, Gao F, He JP, Wu Y, Qiu M, Zhao YL, Su JM, Hou JM and Liu JY: Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl) 89: 595-602, 2011.
38. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO and Ladomery MR: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20: 768-780, 2011.